AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38350888
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of systemic therapy with total ablative therapy (TAT) including surgical resection, microwave ablation, and/or stereotactic ablative body radiotherapy (SABR) for at least one lesion.
Trial: 38350888
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of systemic therapy without total ablative therapy (TAT).
Trial: 38351182
Drug: Nivolumab/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab/radiation therapy
Trial: 38351182
Drug: Nivolumab/ipilimumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab/ipilimumab with concurrent radiotherapy
Trial: 38351528
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life assessment using the Functional Assessment of Cancer Therapy
Trial: 38352207
Drug: Onion Peel
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion Peel Extract (OPE) 1,000 mg/day for 8 weeks
Trial: 38352524
Drug: Digital anal
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital anal rectal examinations (DARE)
Trial: 38353018
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for PHCI
Trial: 38353107
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of neoadjuvant sintilimab + platinum-based chemotherapy
Trial: 38353107
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of neoadjuvant sintilimab + platinum-based chemotherapy
Trial: 38353245
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine program (9-week duration) with recommendations for an anti-inflammatory Mediterranean diet and self-management support
Trial: 38353245
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine program
Trial: 38354138
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of frexalimab intravenously every 4 weeks (with an 1800-mg loading dose)
Trial: 38354138
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of frexalimab subcutaneously every 2 weeks (with a 600-mg loading dose)
Trial: 38354139
Drug: E-cigarettes and
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-cigarettes and e-liquids, standard-of-care smoking-cessation counseling, optional nicotine-replacement therapy
Trial: 38354139
Drug: Standard counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard counseling and a voucher for any purpose (including nicotine-replacement therapy)
Trial: 38354140
Drug: Cefepime-taniborbactam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime-taniborbactam (2.5 g) every 8 hours for 7 days (up to 14 days if bacteremia)
Trial: 38354140
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g) every 8 hours for 7 days (up to 14 days if bacteremia)
Trial: 38354688
Drug: Neoadjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunotherapy (PD1/PD-L1 antibody)
Trial: 38354904
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein treatment (1.6 g/kg per day)
Trial: 38354904
Drug: Usual protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual protein treatment (0.9 g/kg per day)
Trial: 38354904
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein treatment in patients with preexisting malnutrition
Trial: 38354904
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein treatment in patients without preexisting malnutrition
Trial: 38354997
Drug: Gamification strategy
RxNorm normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gamification strategy to increase daily physical activity, including a wearable fitness tracker and a goal to increase daily step count by 33%-50% over 16 weeks.
Trial: 38354997
Drug: Gamification strategy
RxNorm normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gamification strategy to increase daily physical activity.
Trial: 38355180
Drug: WiserAD approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WiserAD approach to antidepressant deprescribing
Trial: 38355397
Drug: 5-mg midodrine
RxNorm normalized name: midodrine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg midodrine
Trial: 38355421
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model based on demographic characteristics, work situation, daily lifestyle, and laboratory tests.
Trial: 38355715
Drug: Kundalini yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kundalini yoga training (KY) - 60-min weekly classes for 12 weeks with daily 12-min homework practice.
Trial: 38355715
Drug: Memory enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory enhancement training (MET) - 12 weekly in-person group classes with 12-min daily homework exercises.
Trial: 38355814
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U300 (Gla-300)
Trial: 38355932
Drug: Salivary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salivary iodine concentration (SIC) < 176 μg/L
Trial: 38355932
Drug: Salivary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salivary iodine concentration (SIC) > 529 μg/L
Trial: 38356344
Drug: Tα1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tα1 treatment
Trial: 38356729
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with sintilimab, paclitaxel, and carboplatin (2 cycles, once every 21 days) followed by concurrent treatment with carboplatin and paclitaxel (5 cycles, once per week) concurrent with radiotherapy (50.4Gy in 28 fractions)
Trial: 38356729
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy only (from previous studies)
Trial: 38356837
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care and SMS reminder
Trial: 38356864
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy in HDUs
Trial: 38356864
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy in ICUs
Trial: 38356882
Drug: Personalized digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized digital speech therapy application
Trial: 38356882
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with a workbook
Trial: 38356884
Drug: Ravulizumab (2,400-3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravulizumab (2,400-3,000 mg loading dose on day 1, followed by 3,000-3,600 mg maintenance doses on day 15 and once every 8 weeks thereafter)
Trial: 38356965
Drug: Entinostat 3-5
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat 3-5 mg and Capecitabine 800 mg
Trial: 38357205
Drug: BCT-100 (1600U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCT-100 (1600U/kg iv weekly)
Trial: 38357391
Drug: peficitinib 100
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: peficitinib 100 mg
Trial: 38357391
Drug: peficitinib 150
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: peficitinib 150 mg
Trial: 38357398
Drug: Half-dose BNT162b2
RxNorm normalized name: Half Beta-Prograne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose BNT162b2 (15 μg)
Trial: 38357398
Drug: Full-dose BNT162b2
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose BNT162b2 (30 μg)
Trial: 38357398
Drug: Half-dose BNT162b2
RxNorm normalized name: Half Beta-Prograne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose BNT162b2 (15 μg) in Gam-COVID-Vac-primed participants
Trial: 38357398
Drug: Full-dose BNT162b2
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose BNT162b2 (30 μg) in Gam-COVID-Vac-primed participants
Trial: 38357797
Drug: SAGE-324/BIIB124 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-324/BIIB124 (60 mg once daily for 28 days)
Trial: 38357797
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 28 days)
Trial: 38357820
Drug: BMS-986141 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986141 (4 mg single oral dose)
Trial: 38357820
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ticagrelor (90 mg BID) and aspirin (75 mg QD)
Trial: 38357820
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg BID)
Trial: 38357820
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg QD)
Trial: 38358253
Drug: Xanthohumol (XN)
RxNorm normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthohumol (XN) supplementation, dosage and duration not specified
Trial: 38358334
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg intravenously every 2 weeks and ipilimumab 1 mg/kg intravenously every 6 weeks
Trial: 38358339
Drug: Zanidatamab (bispecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanidatamab (bispecific anti-HER2 antibody)
Trial: 38358339
Drug: MET inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET inhibitors (single-agent and in combination with zanidatamab)
Trial: 38358423
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (2.5 J, frequency 9.12 Hz, 904 nm for 10 min for 12 sessions)
Trial: 38358542
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus bevacizumab (200 mg and 15 mg/kg respectively) combined with radiotherapy (30-50 Gy/10 fractions)
Trial: 38358753
Drug: pegargiminase-chemotherapy (36.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegargiminase-chemotherapy (36.8 mg/m2 weekly intramuscularly)
Trial: 38358753
Drug: pegargiminase-chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegargiminase-chemotherapy
Trial: 38359838
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with psilocybin-assisted psychotherapy (PAP)
Trial: 38360182
Drug: Brolucizumab 6-mg
RxNorm normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brolucizumab 6-mg
Trial: 38360182
Drug: Aflibercept 2-mg
RxNorm normalized name: aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept 2-mg
Trial: 38360261
Drug: Initial antiseizure
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antiseizure medication (ASM)
Trial: 38360334
Drug: CureSight (binocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CureSight (binocular eye-tracking-based home treatment)
Trial: 38360494
Drug: Daily washing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily washing
Trial: 38360686
Drug: Multi-component pain
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component pain management pathway facilitated by a pain management coordinator including preoperative education, risk identification, personalized analgesic prescriptions, and continued support up to 8 weeks post-op.
Trial: 38360739
Drug: ethinylestradiol/levonorgestrel 30/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethinylestradiol/levonorgestrel 30/150 μg
Trial: 38361371
Drug: Probiotic intervention,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic intervention, details on dosage and duration not specified
Trial: 38362052
Drug: Multidomain intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidomain intervention through the tablet PC SUPERBRAIN application for 24 weeks, including managing metabolic and vascular risk factors, cognitive training, physical exercise, nutritional guidance, and boosting motivation.
Trial: 38362338
Drug: M-atrial natriuretic
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-atrial natriuretic peptide (single subcutaneous injection)
Trial: 38362377
Drug: Precision-based targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision-based targeted therapies
Trial: 38362377
Drug: Precision-based targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision-based targeted therapies in HR+/HER2+ subtype
Trial: 38362466
Drug: FLASH-RT (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLASH-RT (dose rate: 220-270 Gy/s)
Trial: 38362466
Drug: CONV-RT (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONV-RT (dose rate: 0.03-0.06 Gy/sec)
Trial: 38362629
Drug: hyaluronidase-facilitated subcutaneous
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG)
Trial: 38362837
Drug: SAR439459 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR439459 administered intravenously at increasing doses every 2 weeks (Q2W) or every 3 weeks (Q3W) with cemiplimab IV at 3 mg/kg Q2W or 350 mg Q3W.
Trial: 38362837
Drug: SAR439459 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR439459 22.5 mg/kg with cemiplimab 350 mg IV Q3W.
Trial: 38362850
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC), followed by surgery and adjuvant chemotherapy (AC)
Trial: 38362850
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by adjuvant chemotherapy (AC)
Trial: 38363314
Drug: Post-treatment seizures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment seizures
Trial: 38363314
Drug: Mothers having
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mothers having no formal education and lower household monthly income
Trial: 38363571
Drug: COVID-19 positive
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 positive patients receiving chemotherapy (n=110)
Trial: 38363577
Drug: Zilebesiran 150
RxNorm normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilebesiran 150 mg, once every 6 months
Trial: 38363577
Drug: Zilebesiran 300
RxNorm normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilebesiran 300 mg, once every 3 months or every 6 months
Trial: 38363577
Drug: Zilebesiran 600
RxNorm normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilebesiran 600 mg, once every 6 months
Trial: 38363733
Drug: Universal testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal testing and treatment (UTT) as part of the community-level combination HIV prevention package.
Trial: 38363772
Drug: Traditional bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional bread (200 g/d for 8 weeks)
Trial: 38363772
Drug: Control bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control bread (200 g/d for 8 weeks)
Trial: 38363950
Drug: Hip abductor
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip abductor and external rotator strengthening exercises with conventional physical therapy (CPT)
Trial: 38363950
Drug: Proprioceptive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprioceptive training with conventional physical therapy (CPT)
Trial: 38364020
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen (minimum 50 l/min)
Trial: 39318387
Drug: Single-agent cabozantinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent cabozantinib
Trial: 38365118
Drug: Evenly distributing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evenly distributing protein across meals (25-30 g per meal)
Trial: 38365173
Drug: TAU +
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU + WET (Written Exposure Therapy)
Trial: 38365417
Drug: Tafenoquine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine administered to patients with G6PD normal status, aged ≥16 years, not pregnant or breastfeeding.
Trial: 38365417
Drug: G6PD testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G6PD testing before tafenoquine administration.
Trial: 38365417
Drug: Primaquine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine administered to patients with intermediate or normal G6PD status, aged ≥6 months, not pregnant or breastfeeding >1 month.
Trial: 38365437
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of comorbidities (e.g., cancer, obesity, organ transplant)
Trial: 38365502
Drug: CT-P13 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 SC (body weight-based dosing every 2 weeks [Q2W]; W6-54)
Trial: 38365502
Drug: CT-P13 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 IV (5 mg/kg Q8W; W6-22) then CT-P13 SC (Q2W; W30-54)
Trial: 38365694
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) using 980 nm diode laser, 300 mW, twice weekly for 5 weeks (10 sessions)
Trial: 38365694
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% triamcinolone acetonide three times daily with miconazole oral gel once daily for 4 weeks
Trial: 38365744
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glucagon-like peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors
Trial: 38365814
Drug: Model-informed precision
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-informed precision dosing (MIPD) of vancomycin targeting an AUC24h of 400 to 600 mg × h/L
Trial: 39390583
Drug: Standard-of-care dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care dosing and monitoring according to institutional guidelines
Trial: 38365814
Drug: Model-informed precision
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-informed precision dosing (MIPD) of vancomycin
Trial: 38365853
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (SGLT2i) treatment for 12 weeks
Trial: 38365949
Drug: ganfeborole 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ganfeborole 5 mg
Trial: 38365949
Drug: ganfeborole 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ganfeborole 15 mg
Trial: 38365949
Drug: ganfeborole 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ganfeborole 30 mg
Trial: 38365949
Drug: ganfeborole 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ganfeborole 1 mg
Trial: 38365951
Drug: Happy Mother-Healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Happy Mother-Healthy Baby program (anxiety-focused cognitive behavioral therapy, six one-on-one sessions)
Trial: 38365952
Drug: Lower-dose osocimab
RxNorm normalized name: Osocimab
DrugBank: Osocimab (DB14818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose osocimab